All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Durvalumab,Tremelimumab
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020
Details:
AstraZeneca’s Imfinzi received acceptance for its supplemental Biologics License Application and has also been granted Priority Review in the US for a new four-week, fixed-dose regimen for treatment in the approved indications of non-small cell lung cancer and bladder cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bevacizumab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Equidacent
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
Details:
The decision of the European Commission on the approval is expected in September 2020, which would grant Centus the marketing authorization in 27 European Union member states, the United Kingdom and the European Economic Area member states of Norway, Iceland and Liechtenstein.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Belantamab mafodotin
Therapeutic Area: Oncology Product Name: GSK2857916
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2020
Details:
Recommendation is based on data from the DREAMM clinical trial programme, including the pivotal DREAMM-2 study which enrolled heavily pre-treated patients who had actively progressing multiple myeloma that had worsened despite current standard of care.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Durvalumab,Tremelimumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
Data presented at ASCO showed patients treated with a single, priming dose of tremelimumab plus IMFINZI achieved longest median survival among regimens tested.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Idecabtagene vicleucel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bristol-Myers Squibb
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 11, 2020
Details:
Bluebird bio and BMS are redoubling their commitment to ide-cel and optimizing the relationship as they work together to bring this critical treatment to patients in the commercial setting.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Idecabtagene vicleucel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2020
Details:
The presentation will include updated efficacy and safety data from pivotal Phase 2 KarMMa study of ide-cel. Ide-cel is a BCMA-directed genetically modified autologous CAR T cell immunotherapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Acelarin,Cisplatin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2020
Details:
NuTide:121 is a global randomized Phase III study of Acelarin that will enroll up to 828 patients in approximately 120 sites across North America, Europe, Asia and Australia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Olaparib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2020
Details:
Results from the trial showed a statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival with Lynparza vs enzalutamide or abiraterone.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dostarlimab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020
Details:
Dostarlimab provided clinically meaningful results in women with recurrent or advanced mismatch repair-deficient endometrial cancer who progressed on or after a platinum-based regimen.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Durvalumab,Tremelimumab,Etoposide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2020
Details:
High-level results from the final analysis of the Phase III CASPIAN trial showed Imfinzi in combination with a choice of standard-of-care chemotherapies confirmed a sustained overall survival benefit.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
